Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aroa Biosurgery's gross profit for the
six
months ended in Mar. 2026 was A$40.73 Mil. Aroa Biosurgery's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was A$74.07 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Aroa Biosurgery's gross profit for the
six
months ended in Mar. 2026 was A$40.73 Mil. Aroa Biosurgery's Revenue for the
six
months ended in Mar. 2026 was A$47.49 Mil. Therefore, Aroa Biosurgery's Gross Margin % for the quarter that ended in Mar. 2026 was 85.77%.
Aroa Biosurgery had a gross margin of 85.77% for the quarter that ended in Mar. 2026 => Durable competitive advantage
During the past 7 years, the highestGross Margin % of Aroa Biosurgery was 85.73%. The lowest was 69.48%. And the median was 84.90%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Aroa Biosurgery had a gross margin of 85.77% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Aroa Biosurgery Gross Profit Related Terms
Aroa Biosurgery Gross Profit Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aroa Biosurgery's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Gross Profit distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$74.07 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Aroa Biosurgery (ASX:ARX) has a Gross Profit of A$74.07 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Aroa Biosurgery and its competitors.
Is Aroa Biosurgery's Gross Profit too high?
Aroa Biosurgery's current Gross Profit is A$74.07 Mil. Overall, Aroa Biosurgery has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Gross Profit compare to ABT and SYK?
Aroa Biosurgery's Gross Profit of A$74.07 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Aroa Biosurgery and its competitors. Aroa Biosurgery's current Gross Profit is A$74.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.83, compared to a current price of A$0.58 — trading 30.7% below its estimated fair value. The current Gross Profit is A$74.07 Mil. Aroa Biosurgery's overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Gross Profit is A$74.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.58 is trading 30.7% below its estimated GF Value™ of A$0.83.
GuruFocus considers Aroa Biosurgery to be Significantly Undervalued.
Key valuation signals for ASX:ARX:
Gross Profit: A$74.07 Mil
GF Value™: A$0.83 vs. price of A$0.58 (30.7% below fair value)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
58GF Score
Get the complete analysis for ASX:ARX
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
